Toradol to Reduce Ureteroscopy Symptoms Trial (TRUST)

Autor: Jamil S. Syed, Amir Khan, Matthew Goland Van-Ryn, Adam Ludvigson, Piruz Motamedinia
Rok vydání: 2022
Předmět:
Zdroj: Urology. 165:134-138
ISSN: 0090-4295
Popis: To assess the use of intraoperative IV ketorolac (Toradol) on the peri-operative total morphine milligram equivalent (MME) requirements of patients undergoing ureteroscopy for nephrolithiasis.Patients undergoing ambulatory ureteroscopy for nephrolithiasis were randomized to receive ketorolac at time of anesthesia induction. Patients and surgeons were blinded to treatment. Intraoperative, postoperative and combined MME were calculated. Multivariable regression was used to identify independent predictors of MME requirement. Complications were recorded.A total of 94 patients were analyzed following randomization. There were 46 patients in the treatment arm and 48 patients in the control arm. There were no statistically significant differences in gender, age, BMI, operative length or baseline pain medication use between groups (P.05). Patients in the treatment arm required lower intraoperative MME when compared to the control arm (17.1 vs 24, P.01). There were no statistically significant differences in the postoperative MME requirements between groups. The combined peri-operative MME was lower in the treatment arm compared to the control arm (22.2 vs 30.4, P.02). Ketorolac use was an independent predictor of lower MME use on multivariable analysis (beta coefficient -5.1, P.01). There was no statistically significant difference with regards to complication numbers between the treatment arms.Ketorolac during ureteroscopy is associated with a 37% reduction in narcotic requirement and is an independent predictor of decreased peri-operative narcotic needs. These findings show that intra-operative use of ketorolac effectively reduces narcotic requirements and should be considered independently or as part of a multimodal pain control protocol, unless otherwise contraindicated.
Databáze: OpenAIRE